Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Low incidence of ABL-class and JAK-STAT signaling pathway alterations in uniformly treated pediatric and adult B-cell acute lymphoblastic leukemia patients using MRD risk-directed approach – a population-based study

Fig. 3

Event-free survival (EFS) and overall survival (OS) in months in ABL-class or JAK-STAT pathway fusion (AJS)-positive vs. AJS-negative patients. a, all B-ALL patients (7 AJS-positive vs 153 AJS-negative pts); b, adult B-ALL patients (5 AJS-positive vs 33 AJS-negative pts)

Back to article page